The future of ipriflavone in the management of osteoporotic syndromes.
Avioli
L V
LV
Division of Bone and Mineral Diseases, Jewish Hospital of St. Louis, Washington University of Medicine, MO, USA.
D015519:Bone Density / Q000187:drug effects*; D016723:Bone Remodeling / Q000187:drug effects; D005260:Female; D006801:Humans; D007529:Isoflavones / Q000494:pharmacology / Q000627:therapeutic use*; D015337:Multicenter Studies as Topic; D015663:Osteoporosis, Postmenopausal / Q000188:drug therapy* / Q000517:prevention & control; D016032:Randomized Controlled Trials as Topic; D014481:United States; D014486:United States Food and Drug Administration
D007529:Isoflavones; C018986:ipriflavone